GlassScriptPhysician profile
Norma Iglesias
NPI 1083676407
$2,516.61
in general payments reported to CMS, 2019-2025
25 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $226 · 2021: $155 · 2022: $304 · 2023: $284 · 2024: $1,036 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $482.81 | 2020-2024 | Ozempic, Rybelsus |
| Nevro Corp. | $475.03 | 2024 | Senza |
| Abbott Laboratories | $370.88 | 2022-2025 | Jot Dx, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $198.11 | 2019-2024 | Airsupra, Farxiga |
| Medtronic, INC. | $124.41 | 2025 | Synchromedii |
| Bayer Healthcare Pharmaceuticals INC. | $115.43 | 2023 | |
| Lilly USA, LLC | $95.05 | 2021-2024 | Mounjaro, Jardiance |
| Amgen INC. | $76.25 | 2023-2024 | Repatha, Otezla |
| Abbvie INC. | $69.31 | 2021-2024 | |
| Optinose US, INC. | $62.29 | 2022-2025 | |
| Genentech USA, INC. | $57.09 | 2019-2022 | |
| Phadia US INC. | $54.91 | 2022-2024 | Immunocap |
| Myriad Genetic Laboratories, INC. | $50.00 | 2022 | |
| Inspire Medical Systems, INC. | $46.06 | 2024 | Inspire |
| Allergan, INC. | $45.83 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $32.35 | 2020 | |
| Janssen Pharmaceuticals, INC | $24.12 | 2019 | |
| Exact Sciences Corporation | $22.59 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.56 | 2025 | Jardiance |
| Pfizer INC. | $17.96 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.44 | 2024 | Elaprase |
| Insulet Corporation | $16.29 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.64 | 2020 | |
| Upsher-Smith Laboratories LLC | $14.21 | 2021 | |
| Si-Bone, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Iglesias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.